Improved patency of transjugular intrahepatic portosystemic shunt: The efficacy of cilostazol for the prevention of pseudointimal hyperplasia in swine TIPS models

CardioVascular and Interventional Radiology

Volumn 30, Issue 4, 2007, Pages 719-724

  Park, Sang Woo ^a   Cha, In Ho ^b   Kim, Chul Hwan ^c   Jeon, Hae Jeong ^a   Park, Jeong Hee ^a   Hong, Suk Joo ^b   Lee, In Sik ^a  

^a Konkuk University Hospital   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Korea University Ansan Hospital   (South Korea)

Author keywords

Experimental studies; Interventional procedures; Liver

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FOLLOW UP; HEPATIC VEIN; INFERIOR CAVA VEIN; LIVER PARENCHYMA; MICROSCOPY; NONHUMAN; PORTAL VEIN; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STENT; SWINE; TISSUE SECTION;

ADMINISTRATION, ORAL; ANIMALS; ASPIRIN; DISEASE MODELS, ANIMAL; FIBRINOLYTIC AGENTS; FIBROMUSCULAR DYSPLASIA; HEPATIC VEINS; PORTAL VEIN; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; SWINE; TETRAZOLES; VENA CAVA, INFERIOR;

EID: 36049001493     PISSN: 01741551     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00270-007-9001-1     Document Type: Article

References (30)

1. Laberge JM, Somberg KA, Lake JR, et al. (1995) Two year outcome following transjugular intrahepatic portosystemic stent-shunt for variceal bleeding: Results in 90 patients. Gastroenterology 108:1143-1151
2. Luca A, D'Amico G, La Galla R, Midiri M, Morabito A, Pagliaro L (1999) TIPS for prevention of recurrent bleeding in patients with cirrhosis: Meta-analysis of randomized clinical trials. Radiology 212:411-421
3. Papatheodoridis GV, Goulis J, Leandro G, Patch D, Burroughs AK (1999) Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: A meta-analysis. Hepatology 30:612-622
4. Rossle M, Sieterstetter V, Huber M, Ochs A (1998) The first decade of the transjugular intrahepatic portosystemic shunt (TIPS): State of the art. Liver 19:73-89
5. Bilbao JI, Quroga J, Herrero JI, Benito A (2002) Transjugular intrahepatic portosystemic shunt (TIPS): Current status and future possibilities. Cardiovasc Intervent Radiol 25:251-269
6. Nishimine K, Saxon RR, Kichikawa K, et al. (1995) Improved transjugular intrahepatic portosystemic shunt patency with PTFE-covered stent-grafts: Experimental results in swine. Radiology 196:341-347
7. Tanihata H, Saxon RR, Kubota R, et al. (1997) Transjugular intrahepatic portosystemic shunt with silicone-covered Wallstents: Results in a swine model. Radiology 205:181-184
8. Haskal ZJ (1999) Improved patency of transjugular intrahepatic portosystemic shunts in humans: Creation and revision with PTFE stent-grafts. Radiology 213:759-766
9. Haskal ZJ, Davis A, McAllister A, Furth EE (1997) PTFE-encapsulated endovascular stent-graft for transjugular intrahepatic portosystemic shunt: Experimental evaluation. Radiology 205:682-688
10. Otal P, Smayra T, Bureau C, et al. (2002) Preliminary results of a new expanded-polytetrafluoroethylene-covered stent-graft for transjugular intrahepatic portosystemic shunt procedures. AJR Am J Roentgenol 178:141-147
11. Hausegger KA, Karnel F, Georgieva B, et al. (2004) Transjugular intrahepatic portosystemic shunt creation with the Viatorr expanded polytetrafluoroethylene-covered stent-graft. J Vasc Interv Radiol 15:239-248
12. Tsuchikane E, et al. (1999) Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation 100:21-26
13. Umekawa H, Tanaka T, Kimura Y, Hidaka H (1984) Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor Sepharose chromatography. Biochem Pharmacol 33:3339-3344
14. Tanaka T, Ishikawa T, Hagiwara M, et al. (1988) Effect of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology 36:313-320
15. Takahashi S, Oida K, Fujiwara R, et al. (1992) Effect of cilostazol, a cycle AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cell in culture. J Cardiovasc Pharmacol 20:900-906
16. Kubota Y, Kichikawa K, Uchida H, et al. (1995) Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries. Invest Radiol 30:532-537
17. Kamishirado H, Inoue T, Mizoguchi K, et al. (2002) Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis. Am Heart J 144:303-308
18. Zhuang ZW, Hoopes PJ, Koutras PC, et al. (2001) Transjugular intrahepatic portosystemic shunt with an autologous vein-covered stent: Results in a swine model. J Vasc Interv Radiol 12:1333-1342
19. Teng GJ, Betmann MA, Hoopes PJ, Ermeling BL, et al. (1998) Transjugular jugular intrahepatic portosystemic shunt in a porcine model: Histological characteristics a the early stage. Acad Radiol 5:547-555
20. Nazarian GK, Ferral H, Castaneda-Zuniga WR, et al. (1994) Development of stenoses in transjugular intrahepatic portosystemic shunts. Radiology 192:231-234
21. Haskal ZJ, Pentecost MJ, Soulen MC, et al. (1994) Transjugular intrahepatic portosystemic shunt stenosis and revision: Early and midterm results. AJR Am J Roentgenol 163:439-444
22. Teng GJ, Bettmann MA, Hoopes PJ, et al. (1998) Transjugular intrahepatic portosystemic shunt: effect of bile leak on smooth muscle cell proliferation. Radiology 208:799-805
23. Stout LC, Lyon RE, Murray GB, Barth MH (1995) Pseudointimal biliary epithelial proliferation and Azhn's infarct associated with 61/2-month old transjugular intrahepatic portosystemic shunt. Am J Gastroenterol 90:126-130
24. Siegerstetter V, Huber M, Ochs A, Blum HE, Rossle M (1999) Platelet aggregation and platelet-derived growth factor inhibition for prevention of insufficiency of the transjugular intrahepatic portosystemic shunt: A randomized study comparing trapidil plus ticlopidine with heparin treatment. Hepatology 29:33-38
25. Okuda Y, Kimura Y, Yamashita K (1993) Cilostazol. Cardiovasc Drug Rev 11:451-465
26. Mishima Y, Tanabe T, Yasuda K (1986) Clinical evaluation of OPC-13013, a new platelet aggregation inhibitor, on chronic arterial occlusive diseases: Dose finding study by double-blind method. Clin Eval 14:13-41
27. Law MM, Colburn MD, Hajjar GE, et al. (1994) Suppression of intimal hyperplasia in a rabbit model of arterial balloon injury by enalaprilat but not dimethylsulfoxide. Ann Vasc Surg 8:158-165
28. Matsumoto Y, Tani T, Watanabe K, Kimura Y (1992) Effects of cilostazol, an antiplatelet drug, on smooth muscle cell proliferation after endothelial denudation in rats. Jpn J Pharmacol 58:284
29. Sounces JE, Hassall GA, Parrott DP (1992) Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors. Biochem Pharmacol 44:857-866
30. Marx J (1993) Two major signal pathways linked. Science 262:988-900